National Academies Press: OpenBook
« Previous: References
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×

Appendix A

Workshop Agenda

THE GLOBAL CRISIS OF DRUG-RESISTANT TUBERCULOSIS AND THE LEADERSHIP OF THE BRICS COUNTRIES: CHALLENGES AND OPPORTUNITIES

Wednesday–Friday, January 16–18, 2013 Beijing, China

The increasing burden of drug-resistant tuberculosis introduces new challenges to traditional TB control and treatment programs and calls upon the global health community to collaborate and share scientific information in new and different ways. This 3-day workshop is sponsored by the Forum on Drug Discovery, Development, and Translation of the U.S. National Academy of Sciences, the Institute of Medicine (IOM), and the Institute of Microbiology of the Chinese Academy of Sciences (CAS). Following an inaugural meeting in Washington, DC, in 2008, this workshop in Beijing is the fourth in a series of international workshops convened by the U.S. IOM. The objective of the workshop series is to realistically assess the impact of and challenges resulting from drug-resistant TB globally and in the four countries with the most people affected (China, India, Russia, and South Africa). A public workshop was also convened in July/August 2012 in Washington, DC, to identify opportunities to improve the global supply chain for second-line TB drugs. Specifically, the goals of the workshop series include

•   Consider a wide spectrum of issues pertaining to the science and policy around drug-resistant tuberculosis—from biology, epide-

Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×

     miology, and surveillance; to diagnosis, treatment, and infection control; to issues pertaining to the drug supply chain, laboratory capacity, and needs of vulnerable populations. Each workshop will address some or all of these multiple disciplines and facilitate discussion about a global “blueprint for action.”

•   Present promising new research, and also to identify specific gaps in knowledge and consider potential needs for additional research, funding, and international attention.

The workshop series has been hosted over a period of several years, creating a venue and body of knowledge that explicitly considers and addresses developments over a period of time, thus permitting relatively quick adjustments in knowledge and strategy. The workshop series convenes international experts, permitting exchange of information among experts from each of the participating countries and globally. Each workshop in the series results in a U.S. National Academies publication summarizing the workshop presentations and discussions.

This workshop in Beijing will address the current status of drug-resistant tuberculosis globally, and in China, and consider lessons learned from the other three high burden countries; highlight global challenges to controlling the spread of drug-resistant strains; and discuss innovative strategies to advance and harmonize local and international efforts to prevent and treat drug-resistant TB. The workshop will consider urgent themes relating to the problem of multidrug-resistant (MDR) TB, extensively drug resistant (XDR) TB, and emergent TB strains that are potentially untreatable with drugs available and will consider the critical leadership role of the BRICS countries in addressing the threats and opportunities in drug-resistant TB.

THE GLOBAL CRISIS OF DRUG-RESISTANT TUBERCULOSIS AND THE LEADERSHIP OF THE BRICS COUNTRIES: CHALLENGES AND OPPORTUNITIES

Wednesday, January 16, 2013 Beijing, China

DAY 1
 
7:00 a.m. Registration
 
8:30 a.m. Welcome and Introductory Remarks
(Moderator: LIXIN ZHANG)
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
YAPING ZHANG
Vice President
Chinese Academy of Sciences
 
9:00 a.m. Group Photo
 
9:15 a.m. Global Burden, Themes from Institute of Medicine Workshops in Other BRICS Countries, and Workshop Goals

GAIL CASSELL
Chair, IOM Planning Committee
Harvard Medical School
Infectious Disease Research Institute

GEORGE FU GAO
Vice Director General
Chinese Center for Disease Control and Prevention
Beijing Institute of Biological Sciences, CAS
 
9:45 a.m. Opening Keynote Address

Twenty-Five Years After the First Major MDR TB Outbreak: Is It Time for a New Strategy?

PAUL FARMER
Chair, Department of Global Health and Social Medicine Harvard Medical School
 
10:15 a.m. BREAK
 
10:45 a.m.

Panel Discussion: Challenges and Opportunities for the BRICS Country Leadership

The BRICS countries, represented by the Ministers of Health of the Federative Republic of Brazil, the Russian Federation, India, People’s Republic of China, and Republic of South Africa, met in New Delhi on 11 January 2013 at the Second BRICS Health Ministers’ Meeting. The Ministers recognized that multidrug-resistant tuberculosis is a major public health problem for the BRICS countries due to its high prevalence and incidence mostly on the marginalized and vulnerable sections of society. They resolved to

Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×

•   collaborate and cooperate for development of capacity and infrastructure to reduce the prevalence and incidence of tuberculosis through innovation for new drugs/vaccines, diagnostics; and

•   promotion of consortia of tuberculosis researchers to collaborate on clinical trials of drugs and vaccines;

•   strengthening access to affordable medicines and delivery of quality care.

The Ministers also recognized the need to cooperate for adopting and improving systems for notification of tuberculosis patients, availability of anti-tuberculosis drugs at facilities by improving supplier performance, and procurement systems and logistics and management of HIV-associated tuberculosis in the primary health care system.

The Ministers also recognized the importance and need of technology transfer as a means to empower developing countries. In this context, they underlined the important role of generic medicines in the realization of the right to health. The Ministers renewed their commitment to strengthening international cooperation in health, in particular south–south cooperation, with a view to supporting efforts in developing countries to promote health for all and resolve to establish the BRICS network of technological cooperation. (Delhi Communiqué, January 12, 2013, http://pib.nic.in/newsite/erelease.aspx?relid=91533)

RIFAT ATUN

Professor of International Health Management

Imperial College

London

KRISTINA WALLENGREN

Clinical Advisor

KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH)

SALMAAN KESHAVJEE

Associate Professor, Department of Global Health and Social Medicine

Harvard Medical School

Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×

GRIGORY VOLCHENKOV

Head Doctor

Vladimir Oblast TB Dispensary

Center of Excellence for TB Infection Control

YANLIN ZHAO

Vice Director, National Center for Disease Control and Prevention

Director, National Tuberculosis Reference Laboratory

Chinese Center for Disease Control and Prevention

 
11:30 a.m.

Discussion with speakers and audience

Moderators:

GAIL CASSELL

Harvard Medical School

Infectious Disease Research Institute

YANLIN ZHAO

Vice Director, National Center for Disease Control and Prevention

Director, National Tuberculosis Reference Laboratory

Chinese Center for Disease Control and Prevention

 
12:00 p.m. LUNCH
 
SESSION I: DRUG-RESISTANT TB IN CHINA
 

Session Objectives:

•   Describe the health care delivery system in China and recent surveillance results of drug-resistant TB in China. Identify where data are missing and are most needed.

•   Discuss the burden of drug-resistant TB in China from the perspective of clinicians and health care providers.

•   Present data on the burden of drug-resistant TB in vulnerable populations such as domestic migrant workers and individuals with comorbidities, including HIV and diabetes.

•   Present international perspectives on the impact of health delivery systems on DR TB control and care.

Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×

Session Chairs:

•   China co-chair: FABIO SCANO, World Health Organization

•   U.S. co-chair: PAUL FARMER, Harvard Medical School

 
1:30 p.m.

Overview of the Health Care Delivery System and Programmatic Management of MDR TB in China

MINGTING CHEN

Vice Director/Researcher

National Center for Tuberculosis Control and Prevention

Chinese Center for Disease Control and Prevention

 
2:00 p.m.

2007 National Survey of Drug Resistance in China

YANLIN ZHAO

Vice Director, National Center for Disease Control and Prevention

Director, National Tuberculosis Reference Laboratory

Chinese Center for Disease Control and Prevention

 
2:30 p.m.

Panel Discussion: Perspectives from Public Health and Hospital Systems in China
[20 min. each speaker]

Clinical Diagnosis and Treatment of Drug-Resistant TB

WENHONG ZHANG

Huashan Hospital of Fudan University, Shanghai, China

M/XDR TB Chemotherapy in China

SHOU-YONG TAN

Guangzhou Chest Hospital

 
3:10 p.m. BREAK
 
3:30 p.m.

Panel Discussion: Treating Drug-Resistant TB in Vulnerable Populations in China
[20 min. each speaker]

Drug-Resistant TB and HIV in China

LIU FEIYING

Guangxi Center for Disease Control and Prevention, China

Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×

Drug-Resistant TB and Diabetes in China

CHU NAIHUI

(Oral presentation by Duan Hongfei)

Beijing Chest Hospital

 
4:10 p.m. Discussion with speakers and audience
 
4:30 p.m.

Panel Discussion: Impact of Health Care Delivery Systems on DR TB
[20 min. each speaker]

Peru, Russia, and Lesotho

SALMAAN KESHAVJEE

Associate Professor

Department of Global Health and Social Medicine

Harvard Medical School

Community-Based Care in South Africa

KRISTINA WALLENGREN

Clinical Advisor

KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH)

Direct Collaboration and “South-to-South Transfer” in Cambodia and Ethiopia

ANNE GOLDFELD

Harvard Medical School/Global Health Committee

 
5:30 p.m. Discussion with speakers and audience
 
6:00 p.m. Closing remarks and adjourn day 1
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×

THE GLOBAL CRISIS OF DRUG-RESISTANT TUBERCULOSIS AND THE LEADERSHIP OF THE BRICS COUNTRIES: CHALLENGES AND OPPORTUNITIES

Thursday, January 17, 2013 Beijing, China

DAY 2

SESSION II: TRANSMISSION AND INFECTION CONTROL: EPIDEMIOLOGICAL AND GENOTYPIC EVIDENCE AND CONSEQUENCES

Session Objectives:

•   Provide an overview of the epidemiological, phenotypic, and genotypic evidence for primary transmission of drug-resistant TB.

•   Discuss the consequences of transmission of drug-resistant TB in communities and hospitals.

•   Consider the scientific evidence for active case finding, rapid diagnosis, and treatment based on drug-susceptibility testing (DST) to stop transmission.

•   Discuss the role of infection control in China today and consider infection control policies and practices in other countries with a high prevalence of drug-resistant TB.

•   Describe drug-resistant TB risk factors (e.g., inadequate treatment, losing patients during follow-up, drug shortages, exposure to drug-resistant TB due to inadequate infection control) and provide in-country perspectives of the issues and current strategies for prevention and control.

 

Session Chairs:

•   China co-chair: WENHONG ZHANG, Huashan Hospital of Fudan University

•   U.S. co-chair: EDWARD NARDELL, Harvard School of Public Health

 
8:00 a.m.

Global Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics

NEEL GANDHI

Associate Professor

Department of Epidemiology

Rollins School of Public Health

Emory University

Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×

8:30 a.m.

Current Status of Infection Control in China: Different Perspectives
[20 min. each speaker]

Hospital System Perspective

LIANG LI

Clinical Center for Tuberculosis, China CDC

Public Health Systems

GUANGXUE HE

Chinese Center for Disease Control and Prevention

Infection Control Challenges

CAROL RAO

U.S. Centers for Disease Control and Prevention

 
9:30 a.m. Discussion with speakers, panelists and audience
 
10:00 a.m. BREAK
 
10:20 a.m.

Perspectives on Infection Control in Other Countries
[20 min. each speaker]

South Africa

CARRIE TUDOR

Fogarty Global Health Postdoctoral Fellow

Johns Hopkins School of Nursing

Institutional Infection Control in Russia

GRIGORY VOLCHENKOV

Head Doctor

Vladimir Oblast TB Dispensary

Center of Excellence for TB Infection Control

 
11:00 a.m.

Redesign of Health Care Facilities, Active Case Finding, Rapid Diagnosis, and Effective Treatment Based on DST to Stop Transmission in Institutional and Community Settings

EDWARD NARDELL

Associate Professor

Departments of Environmental Health and Immunology and Infectious Diseases, Harvard School of Public Health

Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
11:30 a.m. Discussion with speakers and audience
 
11:45 a.m. LUNCH
 
SESSION III: RAPID DIAGNOSTIC TECHNOLOGY: CURRENT STATUS AND LIMITATIONS 
 

Session Objectives:

•   Provide an overview of the methods of DST used globally and the advantages and disadvantages of different tests.

•   Discuss the current use of diagnostic tests for drug-susceptible and drug-resistant TB in China and identify the barriers to rapid diagnosis and management of patients. Consider challenges in diagnosing TB and drug-resistant TB vs. nontuberculous mycobacteria (NTM). Provide a laboratory- and hospital-based perspective on DST.

•   Discuss work from other countries in implementing programs for rapid diagnosis of drug-resistant TB and consider the populations in which various DSTs work best.

 

Session Chairs:

•   China co-chair: JACK ZHANG, PATH

•   U.S. co-chair: JEAN-LUC BERLAND, Fondation Mérieux

 
1:00 p.m.

DST in Detecting DR TB, Overview of Other Technologies, and Rollout of GeneXpert in South Africa: What Are the Gaps?

MARK NICOL

Division of Medical Microbiology and Institute for Infectious Diseases and Molecular Medicine

University of Cape Town and National Health Laboratory Service

South Africa

 
1:30 p.m.

Panel Discussion: Perspectives on Drug-Resistant TB Diagnostic Technologies in Use in China
[15 min. each speaker]

SAT-TB Assay

JIN CHEN

Shanghai Pulmonary Disease Hospital

Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×

GeneXpert

YAO-JU TAN

Guangzhou Chest Hospital

GenoType MTBDRplus

WEI GE

Shandong Chest Hospital

Line Probe Assay (LPA)

HAIRONG HUANG

Beijing Chest Hospital

Cross Priming Amplification (CPA)

PANG YU

Chinese Center for Disease Control and Prevention

 
2:45 p.m.

Genetic Diversity of DR TB: Implication for Future Diagnostics

MEGAN MURRAY

Professor

Department of Global Health and Social Medicine

Harvard Medical School

 
3:15 p.m. Discussion with speakers and audience
 
3:30 p.m. BREAK
 
Session IV: ADDRESSING DIAGNOSIS AND TREATMENT ACROSS THE SPECTRUM OF DRUG RESISTANCE 
 

Session Objectives:

•   Describe the prevalence of MDR, pre-XDR, XDR, and untreatable TB in key countries.

•   Consider the diagnosis and treatment challenges associated with MDR, pre-XDR, and XDR TB. How can a TB program effectively meet the needs of patients?

 

Session Chairs:

•   China co-chair: JIN LIANG JU, Shanghai Pulmonary Disease Hospital

•   U.S. co-chair: NEEL GANDHI, Emory University

Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
3:45 p.m.

MDR and XDR TB

Clinical Perspective

RICHARD CHAISSON

Johns Hopkins University

 
4:05 p.m.

Panel Discussion: Treating the Spectrum of Drug Resistance in China
[20 min. each speaker]

New Diagnostic Marker Screening in TB Meningitis

XIAOYOU CHEN

Tuberculosis Department, Beijing Chest Hospital

Beijing Tuberculosis & Thoracic Tumor Research Institute

Surgical Treatment of M/XDR TB

XIAO NING

Beijing Chest Hospital, Capital Medical University

 
4:45 p.m.

The Need for a Paradigm Shift in Treatment of the Spectrum of Drug Resistant TB

MARKUS MAEURER

Professor and Head, Therapeutic Immunology Division

Karolinska Institute

 
5:15 p.m.

MDR, XDR, and Untreatable TB from a Laboratory Perspective
[20 min. each speaker]

MARTIE VAN DER WALT

Interim Director, TB Epidemiology and Intervention Research Unit

South African Medical Research Council

SVEN HOFFNER

Director, WHO Supranational TB Reference Laboratory

Associate Professor, Department for Preparedness

Swedish Institute for Communicable Disease Control

Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×

5:55 p.m.

Totally Drug-Resistant TB in India: Lessons and Opportunities from a Clinical Perspective

ZARIR UDWADIA

Consultant Chest Physician

Hinduja Hospital

Mumbai, India

 
6:25 p.m.

Discussion with speakers, panelists, and audience

 
7:15 p.m.

Closing remarks and adjourn day 2

 
THE GLOBAL CRISIS OF DRUG-RESISTANT TUBERCULOSIS AND THE LEADERSHIP OF THE BRICS COUNTRIES: CHALLENGES AND OPPORTUNITIES

Friday, January 18, 2013
Beijing, China

DAY 3
SESSION V: DRUG-RESISTANT TB IN PEDIATRIC POPULATIONS
 

Session Objectives:

•   Review the global burden and transmission of pediatric DR TB.

•   Discuss challenges in diagnosis and treatment of DR TB in children.

 

Session Chairs:

•   China co-chair: QIAN GAO, Fudan University, China

•   U.S. co-chair: MERCEDES BECERRA, Harvard Medical School

 
8:00 a.m.

Children as Sentinels for Transmission and Policy Response

MERCEDES BECERRA

Associate Professor

Department of Global Health and Social Medicine

Harvard Medical School

 
8:30 a.m.

Pediatric Drug-Resistant TB in China

TAO LI

Shanghai Public Health Clinical Center

Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×

8:50 a.m.

Drug-Resistant TB in Meningitis

SHUNYING ZHAO

(Oral presentation by Huimin Li)

Beijing Children’s Hospital

 
9:10 a.m.

Status of Pediatric MDR/XDR TB in the Russian Federation and Other Former Soviet Union Countries: Managing Pediatric Drug-Resistant TB in a Setting with Separate Medical Structures for Adults and Children

VALENTINA AKSENOVA

(Oral presentation by Rita Guenther)

Head, Childhood and Adolescent Tuberculosis Department

Research Institute of Phthisiopulmonology

First Moscow Sechenov State Medical University

Chief Pediatric Phthisiologist, Ministry of Health, Russian Federation

 
9:30 a.m. Discussion with speakers and audience
 
9:45 a.m. BREAK
 
SESSION VI: LOOKING FORWARD: DEVELOPING AND STRENGTHENING THE DRUG SUPPLY CHAIN FOR DRUG-RESISTANT TB
 

Session Objectives:

•   Consider to what extent and in what ways current supply chain mechanisms are or are not effectively accomplishing what is needed, in China and beyond, including consideration of bottlenecks.

•   Consider the current allocation of responsibilities and roles of the private (including industry and not-for-profit public health organizations) and public sectors, and examination of opportunities for enhancing and optimizing collaboration.

•   Identify potential innovative solutions to the supply chain problem.

 

Session Chairs:

•   China co-chair: QIAN GAO, Fudan University, China

•   U.S. co-chair: MERCEDES BECERRA, Harvard Medical School

Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×

10:00 a.m.

Barriers, Challenges, Needs, and Potential Solutions for the SLD Supply Chain

BARRY BLOOM

Co-chair, IOM workshop, Developing and Strengthening the Global Supply Chain for Second-Line Drugs for MDR TB

Distinguished Service Professor

Department of Immunology and Infectious Diseases

Harvard University

Dean of the Harvard School of Public Health (former)

 
10:20 a.m.

Panel: Different Perspectives on the Global Supply Chain

RIFAT ATUN

Professor of International Health Management

Imperial College

London

DAN COLLINS

Corporate Affairs

Eli Lilly and Company

MINGTING CHEN

Chinese Center for Disease Control and Prevention

DALE NORDENBERG

Chief Executive Officer

Novasano Health and Science

OSKAR SLOTBOOM

Head, Vaccine and Infectious Diseases

Xian Janssen Pharmaceutical Ltd., Johnson & Johnson

 
11:30 a.m. Discussion with speakers and audience
 
11:45 a.m. LUNCH
 
SESSION VII: LOOKING FORWARD: EMBRACING A NEW VISION FOR RESEARCH
 

Session Objective:

•   Review the state of the art in TB research and identify opportunities to apply new research tools to the problem of DR TB.

Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×

Session Chairs:

•   China co-chair: MIN FANG, Institute of Microbiology, Chinese Academy of Sciences

•   U.S. co-chair: ANNE GOLDFELD, Harvard Medical School/Global Health Committee

 
1:00 p.m.

The Need for a Paradigm Shift in TB Research: Synergy of Discovery and Delivery of Care

ANNE GOLDFELD

Harvard Medical School/Global Health Committee

 
1:30 p.m.

New Tools to Facilitate TB Research
[10 min. each speaker]

NIH Global TB Research Resources

MARIA GIOVANNI

Director, Office of Genomics and Advanced Technologies

Division of Microbiology and Infectious Diseases

National Institute of Allergy and Infectious Diseases

U.S. National Institutes of Health

TBResist: A Global Consortium for Whole Genome

Sequencing of Drug-Resistant TB

GAIL CASSELL

Harvard Medical School

Infectious Disease Research Institute

Chemogenomics

PATRICK TAO LI

BGI (formerly Beijing Genomics Institute)

Meta-Analysis

KATHRYN DERIEMER

University of California, Davis

 
2:10 p.m. Discussion with speakers, panelists, and audience
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
SESSION VIII: CREATING AN EVIDENCE-BASED BLUEPRINT FOR ACTION: IDENTIFICATION OF FOUR STEPS
 

Session Objective:

•   Present highlights from the workshop and identify a blueprint for action based on discussions from the previous 2.5 days.

 

Session Chairs:

•   China co-chair: YANLIN ZHAO, Chinese Center for Disease Control and Prevention

•   U.S. co-chair: GAIL CASSELL, Harvard Medical School and Infectious Disease Research Institute

 
2:30 p.m.

Action #1: Expose and Address the Silent Epidemic of DR TB in Children: Evidence Challenges and Mobilization of a Global Network

MERCEDES BECERRA

Associate Professor

Department of Global Health and Social Medicine

Harvard Medical School

QIAN GAO

Fudan University, Shanghai

 
2:45 p.m.

Action #2: Adopt Genomic Tools to Map the Epidemic of Drug-Resistant TB and Address Diagnostic Challenges

SVEN HOFFNER

Director, WHO Supranational TB Reference Laboratory

Associate Professor, Department for Preparedness

Swedish Institute for Communicable Disease Control

YANLIN ZHAO

Vice Director, National Center for Disease Control and Prevention

Director, National Tuberculosis Reference Laboratory

Chinese Center for Disease Control and Prevention

Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×

3:00 p.m.

Action #3: Block Transmission of Drug-Resistant TB

EDWARD NARDELL

Associate Professor

Departments of Environmental Health and Immunology and Infectious Diseases

Harvard School of Public Health

LIXIN ZHANG

Deputy Director, CAS Key Laboratory of Pathogenic Microbiology & Immunology

Inaugural Director of Drug Discovery Center for Tuberculosis

Institute of Microbiology, Chinese Academy of Sciences

 
3:15 p.m.

Action #4: Revolutionize Drug Distribution, Guarantee Drug Quality, and Reform Regulatory Approval and Registration Policies

BARRY BLOOM

Distinguished Service Professor

Department of Immunology and Infectious Diseases

Harvard University

Dean of the Harvard School of Public Health (former)

 
3:30 p.m. BREAK
 
SESSION IX: A BIOSOCIAL APPROACH: SCIENCE AND ECONOMIC INTERVENTION FOR DR TB CONTROL—BRICS AT THE FOREFRONT
 

Session Objective:

•   Discuss the leading role of BRICS countries in the effort to combine science and evidence-based policies with economic interventions to combat DR TB.

 

Session Chairs:

•   China co-chair: YANLIN ZHAO, Chinese Center for Disease Control and Prevention

•   U.S. co-chair: RIFAT ATUN, Professor of International Health Management, Imperial College London

Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×

3:45 p.m.

What Will Be Required for Zero Deaths from Drug-Resistant TB?

SALMAAN KESHAVJEE

Associate Professor

Department of Global Health and Social Medicine

Harvard Medical School

4:15 p.m.

Reflections from BRICS Countries: What Are the Next Steps?

RIFAT ATUN

Professor of International Health Management

Imperial College

London

PAUL FARMER

Chair, Department of Global Health and Social Medicine

Harvard Medical School

KRISTINA WALLENGREN

Clinical Advisor

KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH)

GRIGORY VOLCHENKOV

Head Doctor

Vladimir Oblast TB Dispensary

Center of Excellence for TB Infection Control

YANLIN ZHAO

Vice Director, National Center for Disease Control and Prevention

Director, National Tuberculosis Reference Laboratory

Chinese Center for Disease Control and Prevention

 
5:15 p.m. Discussion with speakers and audience
 
6:00 p.m.

Reflections on the New Delhi Communiqué

JARBAS BARBOSA (by teleconference)

Vice-Minister of Health

Federative Republic of Brazil

Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
6:15 p.m. Adjourn day 3 and workshop
 
7:00 p.m. BANQUET
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
Page 151
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
Page 152
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
Page 153
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
Page 154
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
Page 155
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
Page 156
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
Page 157
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
Page 158
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
Page 159
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
Page 160
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
Page 161
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
Page 162
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
Page 163
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
Page 164
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
Page 165
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
Page 166
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
Page 167
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
Page 168
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
Page 169
Suggested Citation:"Appendix A: Workshop Agenda." Institute of Medicine. 2014. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences. Washington, DC: The National Academies Press. doi: 10.17226/18346.
×
Page 170
Next: Appendix B: Participant Biographies »
The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences Get This Book
×
Buy Paperback | $48.00 Buy Ebook | $38.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Multidrug-resistant tuberculosis (TB) is caused by bacteria resistant to isoniazid and rifampicin, the two most effective first-line anti-TB drugs, originally developed and introduced in the 1950 and 1960s. Since 2008, the Forum on Drug Discovery, Development, and Translation of the Institute of Medicine has hosted or co-hosted six domestic and international workshops addressing the global crisis of drug-resistant TB, with special attention to the BRICS countries - Brazil, Russia, India, China, and South Africa.

The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS is the summary of a workshop convened to address the current status of drug-resistant TB globally and in China. This report considers lessons learned from high burden countries; highlights global challenges to controlling the spread of drug-resistant strains; and discusses innovative strategies to advance and harmonize local and international efforts to prevent and treat drug-resistant TB. Additionally, the report examines the problem of MDR TB and emergent TB strains that are potentially untreatable with drugs available and considers the critical leadership role of the BRICS countries in addressing the threats and opportunities in drug-resistant TB.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!